**Supplementary material**

Adverse events in the overall population and in different treatment groups.

|  |  |  |  |
| --- | --- | --- | --- |
| **Adverse Events** | **Standard Dose (N = 108)** | **Reduced Dose (N = 50)** | **p-value** |
| Neutropenia | 21 (19.4%) | 11 (22.0%) | 0.711 |
| Asthenia | 6 (5.6%) | 7 (14.0%) | 0.073 |
| Diarrhea | 7 (6.5%) | 0 | 0.098 |
| Cardiac disorders | 2 (1.9%) | 0 | 1.000 |
| Anemia | 6 (5.6%) | 1 (2.0%) | 0.433 |
| Thrombocitopenia | 2 (1.9%) | 0 | 1.000 |
| Alopecia | 0 | 1 (2.0%) | 0.318 |

|  |  |  |  |
| --- | --- | --- | --- |
| **Grade of Adverse Events** | **Ademaciclib**  **Standard Dose (N = 29)** | **Ademaciclib**  **Reduced Dose (N = 19)** | **p-value** |
| No adverse events | 1 (3.4%) | 1 (5.3%) | 1.000 |
| Grade 1 | 5 (17.2%) | 7 (36.8%) | 0.129 |
| Grade 2 | 12 (41.4%) | 4 (21.1%) | 0.148 |
| Grade 3 | 11 (37.9%) | 6 (31.6%) | 0.656 |
| Grade 2, 3, or 4 | 23 (82.1%) | 10 (55.6%) | 0.053 |
| Temporary interruption | 20 (69.0%) | 8 (42.1%) | 0.068 |
| Permanent discontinuation | 10 (34.5%) | 7 (36.8%) | 0.869 |

|  |  |  |  |
| --- | --- | --- | --- |
| **Grade of Adverse Events** | **Ribociclib**  **Standard Dose (N = 38)** | **Ribociclib**  **Reduced Dose (N = 15)** | **p-value** |
| No adverse events | 12 (31.6%) | 3 (20.0%) | 0.404 |
| Grade 1 | 6 (15.8%) | 4 (26.7%) | 0.367 |
| Grade 2 | 7 (18.4%) | 6 (40.0%) | 0.103 |
| Grade 3 | 10 (26.3%) | 2 (20.0%) | 0.314 |
| Grade 4 | 1 (2.6%) | 0 | 1.000 |
| Grade 2, 3, or 4 | 18 (69.2%) | 8 (66.7%) | 0.876 |
| Temporary interruption | 17 (44.7%) | 4 (26.7%) | 0.230 |
| Permanent discontinuation | 10 (26.3%) | 1 (6.7%) | 0.116 |

|  |  |  |  |
| --- | --- | --- | --- |
| **Grade of Adverse Events** | **Palbociclib**  **Standard Dose (N = 41)** | **Palbociclib**  **Reduced Dose (N = 16)** | **p-value** |
| No adverse events | 6 (14.6%) | 2 (12.5%) | 0.836 |
| Grade 1 | 7 (17.1%) | 6 (37.5%) | 0.102 |
| Grade 2 | 11 (26.8%) | 4 (25.0%) | 0.889 |
| Grade 3 | 14 (34.1%) | 3 (18.8%) | 0.258 |
| Grade 2, 3, or 4 | 25 (71.4%) | 7 (50.0%) | 0.159 |
| Temporary interruption | 18 (43.9%) | 6 (37.5%) | 0.663 |
| Permanent discontinuation | 11 (26.8%) | 7 (43.7%) | 0.221 |